Maple Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Maple Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-14,000	Closed	-$117K	–	141
2017 Q1	$117K	Hold	14,000	–	–	0.03%	132
2016 Q4	$97K	Hold	14,000	–	–	0.03%	122
2016 Q3	$71K	Hold	14,000	–	–	0.02%	125
2016 Q2	$84K	Hold	14,000	–	–	0.03%	111
2016 Q1	$64K	Hold	14,000	–	–	0.02%	117
2015 Q4	$63K	Hold	14,000	–	–	0.02%	125
2015 Q3	$44K	Hold	14,000	–	–	0.02%	121
2015 Q2	$42K	Hold	14,000	–	–	0.01%	125
2015 Q1	$41K	Hold	14,000	–	–	0.01%	126
2014 Q4	$62K	Buy	+14,000	New	+$66.8K	0.02%	127

Other funds holding ENZ

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Maple Capital Management's ENZ Position: Q2 2017 in Review

Maple Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2017, closing a stake of 14,000 shares — an estimated $117K sold.

Maple Capital Management first reported a position in ENZ in Q4 2014 and held it in 10 quarters. The position peaked at $117K in Q1 2017. 120 funds tracked by Wall St. Rank hold ENZ as of Q2 2017.

Maple Capital Management reported no remaining Enzo Biochem, Inc. position as of Q2 2017 after selling out during the quarter.
Maple Capital Management sold 14,000 Enzo Biochem, Inc. shares in Q2 2017, an estimated $117K.
Maple Capital Management first reported a position in Enzo Biochem, Inc. in Q4 2014 and held it in 10 quarters.
Maple Capital Management's Enzo Biochem, Inc. position peaked at $117K in Q1 2017.
120 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2017.

Based on Maple Capital Management's 13F filing for Q2 2017, filed 19 Jul 2017.